-$0.61 EPS Expected for Neon Therapeutics Inc (NASDAQ:NTGN) This Quarter

Analysts expect that Neon Therapeutics Inc (NASDAQ:NTGN) will report earnings of ($0.61) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Neon Therapeutics’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.46). Neon Therapeutics posted earnings of ($0.67) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 9%. The company is expected to issue its next earnings report on Monday, November 11th.

On average, analysts expect that Neon Therapeutics will report full-year earnings of ($2.51) per share for the current year, with EPS estimates ranging from ($3.18) to ($1.85). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.28) per share, with EPS estimates ranging from ($4.17) to ($1.42). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.01).

Several equities research analysts have recently issued reports on the stock. Morgan Stanley reduced their price objective on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 16th. Zacks Investment Research upgraded shares of Neon Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Saturday, October 12th. ValuEngine upgraded shares of Neon Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Mizuho set a $21.00 price objective on shares of Neon Therapeutics and gave the company a “buy” rating in a research report on Monday, September 30th. Finally, Robert W. Baird assumed coverage on shares of Neon Therapeutics in a research report on Thursday, July 25th. They set an “outperform” rating and a $15.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $13.00.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace North America L.P. bought a new stake in Neon Therapeutics in the first quarter worth $49,000. Westfield Capital Management Co. LP bought a new stake in Neon Therapeutics in the second quarter worth $149,000. Morgan Stanley increased its position in Neon Therapeutics by 10.8% in the second quarter. Morgan Stanley now owns 40,522 shares of the company’s stock worth $192,000 after purchasing an additional 3,939 shares during the last quarter. Bank of New York Mellon Corp increased its position in Neon Therapeutics by 112.1% in the second quarter. Bank of New York Mellon Corp now owns 71,443 shares of the company’s stock worth $339,000 after purchasing an additional 37,755 shares during the last quarter. Finally, Northern Trust Corp increased its position in Neon Therapeutics by 8.5% in the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock worth $789,000 after purchasing an additional 12,971 shares during the last quarter. Institutional investors own 67.10% of the company’s stock.

Neon Therapeutics stock opened at $2.19 on Friday. The company has a current ratio of 6.13, a quick ratio of 6.13 and a debt-to-equity ratio of 0.12. Neon Therapeutics has a 1 year low of $1.61 and a 1 year high of $8.85. The firm’s 50 day moving average price is $2.29 and its 200-day moving average price is $4.04.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Recommended Story: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.